A 28 to 54-Week, Open-Label, Multicenter Study to Assess the Long-Term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension.

Trial Profile

A 28 to 54-Week, Open-Label, Multicenter Study to Assess the Long-Term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2015

At a glance

  • Drugs Aliskiren/amlodipine/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 15 Mar 2012 This trial is recruting in Spain as reported by European Clinical Trials Database.
    • 30 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jan 2009 Additional locations identified as reported by ClinicalTrials.gov, last updated 7-Jan-2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top